Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMO959 + 177Lu-vipivotide tetraxetan with or without ARPI in PSMA-positive metastatic castration-resistant prostate cancer
jRCT2011250073Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Phase 2, open-label trial of luxdegalutamide, lutetium lu 177 vipivotide tetraxetan, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Novartis. Primary endpoints: Incidence rate of dose-limiting toxicities, Incidence rate of adverse events and serious adverse events and 4 more. Started Oct 2026; status: recruiting.
02
Drugs
luxdegalutamidelutetium lu 177 vipivotide tetraxetanabirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2011250073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250073.